Tenax Therapeutics (TENX) Total Non-Current Liabilities (2012 - 2022)
Tenax Therapeutics recorded quarterly Total Non-Current Liabilities of $64196.0 in Q4 2022, down 32.67% quarter-over-quarter from $95347.0 in Q3 2022, and down 65.03% year-over-year from $183589.0 in Q4 2021.
Tenax Therapeutics' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $64196.0 for Q4 2022.
- In Q4 2022, Total Non-Current Liabilities fell 65.03% year-over-year to $64196.0; the TTM figure through Dec 2022 stood at $64196.0 (down 65.03% YoY), while the FY2022 annual figure was $64196.0, down 65.03% from the prior year.
- Total Non-Current Liabilities came in at $64196.0 for Q4 2022 at Tenax Therapeutics, down from $95347.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.6 million in Q4 2018 to a low of $31080.0 in Q1 2021.
- A 5-year average of $296837.4 and a median of $169306.5 in 2021 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 96.11% in 2019 and surged 398.79% in 2022, its largest moves.
- Tenax Therapeutics' Total Non-Current Liabilities stood at $1.6 million in 2018, then tumbled by 96.11% to $60379.0 in 2019, then soared by 105.64% to $124166.0 in 2020, then soared by 47.86% to $183589.0 in 2021, then tumbled by 65.03% to $64196.0 in 2022.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $64196.0, $95347.0, and $125883.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 64,196.00 |
| Sep 30, 2022 | 95,347.00 |
| Jun 30, 2022 | 125,883.00 |
| Mar 31, 2022 | 155,024.00 |
| Dec 31, 2021 | 183,589.00 |
| Sep 30, 2021 | 211,590.00 |
| Jun 30, 2021 | 239,039.00 |
| Mar 31, 2021 | 31,080.00 |
| Dec 31, 2020 | 124,166.00 |
| Sep 30, 2020 | 213,757.00 |
| Jun 30, 2020 | 137,051.00 |
| Dec 31, 2019 | 60,379.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | 496,782.00 |
| Jun 30, 2018 | 768,240.00 |
| Mar 31, 2018 | 290,339.00 |
| Dec 31, 2017 | 975,167.00 |
| Sep 30, 2017 | 802,474.00 |
| Jun 30, 2017 | 2.11 Mn |
| Mar 31, 2017 | 4.99 Mn |
| Dec 31, 2016 | 6.14 Mn |
| Sep 30, 2016 | 12.71 Mn |
| Jun 30, 2016 | 12.87 Mn |
| Mar 31, 2016 | -293,438.00 |
| Dec 31, 2015 | 12.04 Mn |
| Apr 30, 2015 | -71.00 Mn |
| Jan 31, 2015 | -579,660.00 |
| Oct 31, 2014 | -716,759.00 |
| Jul 31, 2014 | -680,680.00 |
| Apr 30, 2014 | -82.82 Mn |
| Jan 31, 2014 | -1.08 Mn |
| Apr 30, 2013 | 4.96 Mn |
| Jan 31, 2013 | 4.58 Mn |
| Oct 31, 2012 | 3.52 Mn |